Nutritional therapy is essential for the prevention of toxic amyloid beta oligomerization with relevance to diet and Alzheimer’s disease

The role of nutrients in dietary fibre will be assessed to regulate cholesterol and amyloid beta concentrations that are risk factor for Alzheimer’s disease. The peripheral sink amyloid beta hypothesis in AD requires assessment of amyloid beta oligomers that determine liver membrane toxicity and clearance. Nutritional therapy will determine correct proteomic interactions that prevent rapid amyloid beta assembly with amyloid formation. Developments in oligomeric amyloid beta using technologies from industry will allow evaluation of interactions between nutritional agents and amyloid beta structures. Static light scattering technology will be used to assess the synthetic amyloid beta oligomeric amyloid beta aggregation and molecular weight determination. Assessment of nutritional agents tested may change amyloid beta proteins to physiological significance of amyloid beta oligomers in solution. Static light scattering assessment may assist with AFM interpretation and may allow assessment of the physiological significance of amyloid beta oligomers in solution. Static light scattering allow quality control for biological experiments. In alliance with industry specific food components identified from dietary fibre allow assessment of amyloid beta toxicity with the prevention of NAFLD and AD.